Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

OostNL backs the €18.5M Series B funding round of this Dutch biotech company that’s fighting cancer

Editorial team by Editorial team
February 15, 2021
in (Crowd)funding, Health & Medtech, News
0
Cancer

Image credit: LinkedIn

24
SHARES
LinkedInTwitterWhatsAppFacebook

Netherlands-based InteRNA Technologies, a biopharma company that develops microRNA (miRNA)-based therapeutics for oncology, has announced the close of its Series B round with extended funding of €18.5M in total.

Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

Investors in the current round

This Series B round was led by AurorA Science, an Italian biotech investment company. Existing investor Waterman Ventures as well as current investors Aglaia Oncology Funds and OostNL also participated in this round.

With this funding, Gabriele Campi, PhD, of AurorA Science will join the InteRNA Technologies’ board of directors.

What is InteRNA Technologies working on?

Led by CEO Roel Schaapveld, InteRNA Technologies is a spin-off from the Hubrecht Institute, Utrecht, Netherlands. It is a clinical-stage biotech company developing products of microRNA (miRNA) therapeutics targeting key processes in the initiation and progression of human diseases, with a focus on cancer.

According to the company, “microRNAs are naturally occurring, non-coding strands of RNA that trigger the RNA interference pathway and regulate gene expression by controlling the efficiency of messenger RNA (mRNA) translation into functional proteins.” 

InteRNA claims to design therapies tackling cancer by using the inherent characteristic of microRNAs to simultaneously inhibit multiple mRNA targets in a coordinated fashion, e.g. by blocking activated cancer signalling pathways and preventing activation of alternative disease-promoting pathways.

Image credit: InteRNA Technologies

Selected through InteRNA’s discovery and functional validation platform, miRNA, and enabled with a 3rd generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging multiple signal transduction targets simultaneously.

“With this approach, we address the high need for novel therapeutics with improved efficacy and less prone to drug-acquired resistance that will benefit cancer patients,” said the company in a statement.

Use of the funds

With this raised capital, InteRNA Technologies says it will start the clinical evaluation of its microRNA lead candidate, INT-1B3, in patients with advanced solid tumours. “This successful extension of the Series B financing round validates the unique potential that microRNAs offer as a therapeutic modality for hard-to-treat cancers,” says Dr Roel Schaapveld, CEO of InteRNA Technologies.

In addition to that, the funds will also enable the company to develop and advance additional preclinical drug candidates addressing a variety of cancer indications, hence, expanding its product pipeline.

Dr Schaapveld further claims that he looks forward to evaluating INT-1B3’s unique mode of action, targeting not only the tumour cells themselves but also the disease-promoting tumour microenvironment.”

According to the company, INT-1B3 is a lipid nanoparticle (LNP) formulated, chemically modified miR-193a-3p mimic that can be delivered by systemic administration to cancer cells.

Last year, in May, InteRNA Technologies received regulatory approvals in the Netherlands and Belgium for the initiation of the first-in-human (Phase I) clinical trial testing its lead microRNA candidate, INT-1B3, in patients with advanced solid tumours.

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Nebula CTO Andre Witte
Cloud spend management 😱
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the...Show More
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the costs at bay in 2021. Show Less
Read more
Tags: fundinghealthnews
Share2Tweet6SendShare10

Featured events

07apr10:0012:30FeaturedWorkshop: pr for startupsHow to grow your startup with the help of public relations

Partner content | Work with us

Blue Tulip Awards celebrates International Women’s Day: maximum performance can only come from a diverse team

Future Hamburg Award: Looking for the best startups to forge the city of the future

The Humblebrag launches online course to help emerging leaders amplify their visibility and voice

Blue Tulip Awards announce 5 finalists in the Food & Water and Education & Employment theme

Impact media foundation 5 Media offers grants up to €100,000 per year to drive a sustainable future

Breaking news from Amsterdam | Partner

Amsterdam’s Crisp raises €30M: Here’s what this online-only supermarket plans to do with this capital

Amsterdam-based Tellow’s parent company raises €60.2M: An interview with Thomas Vles, Tellow’s new CEO

Amsterdam-based fast-charging startup Fastned charges itself with €150M through accelerated bookbuild offering

Amsterdam-based Founda Health raises €12.3M to build infrastructure for global healthcare sector; here’s how

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info